Compare FSTR & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSTR | RNA |
|---|---|---|
| Founded | 1902 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.8M | 227.6M |
| IPO Year | 1995 | 2025 |
| Metric | FSTR | RNA |
|---|---|---|
| Price | $28.09 | $13.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 20 |
| Target Price | $32.00 | ★ $69.26 |
| AVG Volume (30 Days) | 25.9K | ★ 1.5M |
| Earning Date | 03-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $540,009,000.00 | N/A |
| Revenue This Year | $5.12 | $88.12 |
| Revenue Next Year | $2.78 | $18.11 |
| P/E Ratio | $40.58 | ★ N/A |
| Revenue Growth | ★ 1.74 | N/A |
| 52 Week Low | $17.16 | $11.95 |
| 52 Week High | $32.63 | $73.06 |
| Indicator | FSTR | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.53 | 8.72 |
| Support Level | $27.26 | $13.06 |
| Resistance Level | $29.43 | $72.75 |
| Average True Range (ATR) | 1.03 | 0.70 |
| MACD | -0.02 | 1.55 |
| Stochastic Oscillator | 53.37 | 31.25 |
L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.